01242nas a2200433   4500008004100000022001400041245004300055210004000098260004200138300000600180490000700186653001900193653002200212653001500234653002400249653001500273653001500288653001500303653002600318653001400344653002200358653001900380653003200399653002900431653001000460653002300470653002100493653002700514653001700541653002400558653002900582653003300611653002600644653004500670653002200715100001800737700002300755856003000778       2020                        eng d  a1927-032100aEditorial: ISPIM Bangkok (August 2020)0 aEditorial ISPIM Bangkok August 2020  aOttawabTalent First Networkc08/2020  a30 v1010aBasic research10abiotech startups.10aco-working10aConceptual research10adisruption10aincubators10ainnovation10aIntegrative marketing10ainvestors10aknowledge-sharing10aOpen marketing10aorganizational capabilities10aPharmaceutical companies10aroles10aservice ecosystems10aservice entities10aservice-dominant logic10astakeholders10astrategic marketing10astrategy-innovation link10astructured literature review10atriadic relationships10aUniversity and Public research institute10avalue co-creation1 aTanev, Stoyan1 aSandstrom, Gregory  utimreview.ca/article/138002029nas a2200217   4500008004100000022001400041245010600055210006900161260004200230300001000272490000700282520131800289653001901607653002201626653001501648653002901663653004501692100002301737700002101760856003001781       2020                        eng d  a1927-032100aWhich Factors Influence a Company’s Evaluation of the Contribution of Basic Research to Innovation?0 aWhich Factors Influence a Company s Evaluation of the Contributi  aOttawabTalent First Networkc08/2020  a38-510 v103 aThis paper empirically analyses how individuals in companies evaluate the contributions of basic research by universities and public research institutes to industry from multiple perspectives: manager as a spokesperson of the company (science-based industry or others), position within the company (managers or inventors), affiliations of inventors (large pharmaceutical companies or biotech start-ups), and educational background. This paper focuses on the case of Japan. Questionnaire surveys were sent to managers and inventors in established companies and start-ups across several industries. This study found that, 1) the more science-oriented the company, the higher their managers evaluate academic research, 2) inventors evaluate academic research more highly than managers, 3) inventors from biotech start-ups evaluate academic research more highly than inventors from large companies in the pharmaceutical industry, and 4) the more advanced their educational background, the more highly inventors evaluate academic research. This study suggests that 'closeness to science' is an important factor for companies to evaluate contributions of basic research to innovation. The findings also suggest that problems within the current educational system are an indirect cause of the innovation crisis in Japan.10aBasic research10aBiotech start-ups10ainnovation10aPharmaceutical companies10aUniversity and Public research institute1 aNagane, Hiromi, S.1 aSumikura, Koichi  utimreview.ca/article/1379